Helix BioPharma Corp. Announces Changes to the Company’s Board of Directors and Management

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Heman Chao has notified the Board of Directors of the Company of his intention to step down from the position of Chief Executive Officer (“CEO”), Chief Scientific Officer (“CSO”) and member of the Board, effective September 1, 2021. As of September 1, 2021, Mr. Chao will assume the position of Chair of the Company’s Scientific Advisory Board.

20210630-HBP-PR-Resignation-of-CEO-FINAL